YAP1 and pulmonary arterial hypertension: YAP/TAZ activation also contributes to PAH severity by suppressing anti-inflammatory and vasodilatory cyclooxygenase-2 and prostaglandin F1α in a TEAD-dependent fashion in PASMC (190).